{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:20:46Z","timestamp":1783146046508,"version":"3.54.6"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12072-026-11088-2","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:17:49Z","timestamp":1778249869000},"page":"587-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New therapies for primary biliary cholangitis"],"prefix":"10.1007","volume":"20","author":[{"given":"Aalam","family":"Sohal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Alamgir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"1","key":"11088_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","volume":"114","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Bernstein D, Shiffman ML, et al. Diagnosis and management of Primary Biliary Cholangitis. Am J Gastroenterol. 2019;114(1):48\u201363. https:\/\/doi.org\/10.1038\/s41395-018-0390-3","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"11088_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.cld.2022.06.011","volume":"26","author":"AM Sy","year":"2022","unstructured":"Sy AM, Ferreira RD, John BV. Hepatocellular carcinoma in Primary Biliary Cholangitis. Clin Liver Dis. 2022;26(4):691\u2013704. https:\/\/doi.org\/10.1016\/j.cld.2022.06.011","journal-title":"Clin Liver Dis"},{"issue":"6","key":"11088_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000179","volume":"7","author":"J Trivella","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6): e0179. https:\/\/doi.org\/10.1097\/HC9.0000000000000179. (Published 2023 Jun 2)","journal-title":"Hepatol Commun"},{"key":"11088_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/HMER.S361077","volume":"15","author":"A Sohal","year":"2023","unstructured":"Sohal A, Kowdley KV. Primary Biliary Cholangitis: promising emerging innovative therapies and their impact on GLOBE scores. Hepatol Med Policy. 2023;15:63\u201377. https:\/\/doi.org\/10.2147\/HMER.S361077. (PMID: 37312929; PMCID: PMC10259525.)","journal-title":"Hepatol Med Policy"},{"key":"11088_CR5","unstructured":"Data accessed from \u201chttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/020675s028lbl.pdf\u201d"},{"issue":"6","key":"11088_CR6","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","volume":"147","author":"WJ Lammers","year":"2014","unstructured":"Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with Primary Biliary Cirrhosis: an international follow-up study. Gastroenterology. 2014;147(6):1338-1349.e5. https:\/\/doi.org\/10.1053\/j.gastro.2014.08.029","journal-title":"Gastroenterology"},{"issue":"17","key":"11088_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175713","volume":"12","author":"F Martini","year":"2023","unstructured":"Martini F, Balducci D, Mancinelli M, et al. Risk stratification in Primary Biliary Cholangitis. J Clin Med. 2023;12(17): 5713. https:\/\/doi.org\/10.3390\/jcm12175713. (PMID: 37685780; PMCID: PMC10488776.)","journal-title":"J Clin Med"},{"issue":"7","key":"11088_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. 2016;375(7):631\u2013643. https:\/\/doi.org\/10.1056\/NEJMoa1509840","journal-title":"N Engl J Med"},{"key":"11088_CR9","unstructured":"Center for Drug Evaluation and Research. Due to serious liver injury risk, FDA restricts use of Ocaliva. U.S. Food and Drug Administration. 2024 Dec 12. Available from: FDA Drug Safety Communication"},{"key":"11088_CR10","unstructured":"Accessed from \u201chttps:\/\/www.federalregister.gov\/documents\/2025\/11\/24\/2025-20767\/intercept-pharmaceuticals-inc-et-al-withdrawal-of-approval-of-new-drug-application-for-ocaliva\u201d"},{"issue":"4","key":"11088_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0016-5085(19)32419-9","volume":"69","author":"JA Summerfield","year":"1975","unstructured":"Summerfield JA, Elias E, Sherlock S. Effects of clofibrate in Primary Biliary Cirrhosis hypercholesterolemia and gallstones. Gastroenterology. 1975;69(4):998\u20131000","journal-title":"Gastroenterology"},{"key":"11088_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","volume":"16","author":"S Iwasaki","year":"1999","unstructured":"Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T. Bezafibrate may have a beneficial effect in pre-cirrhotic Primary Biliary Cirrhosis. Hepatol Res. 1999;16:12\u201318","journal-title":"Hepatol Res"},{"issue":"6","key":"11088_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","volume":"38","author":"S Iwasaki","year":"2008","unstructured":"Iwasaki S, Ohira H, Nishiguchi S, Zeniya M, Kaneko S, Onji M, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for Primary Biliary Cirrhosis: a prospective, multicenter study. Hepatol Res. 2008;38(6):557\u2013564","journal-title":"Hepatol Res"},{"issue":"1","key":"11088_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","volume":"95","author":"S Nakai","year":"2000","unstructured":"Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in Primary Biliary Cirrhosis: a preliminary study. Am J Gastroenterol. 2000;95(1):326\u2013327 (PMID: 10638623.)","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"11088_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1572-0241.2002.05413.x","volume":"97","author":"T Kurihara","year":"2002","unstructured":"Kurihara T, Maeda A, Shigemoto M, Yamashita K, Hashimoto E. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long-term monotherapy. Am J Gastroenterol. 2002;97(1):212\u2013214 (PMID: 11808959)","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"11088_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ajg.2015.20","volume":"110","author":"K Hosonuma","year":"2015","unstructured":"Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Horiguchi N, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110(3):423\u2013431. https:\/\/doi.org\/10.1038\/ajg.2015.20","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"11088_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/apt.13465","volume":"43","author":"AC Cheung","year":"2016","unstructured":"Cheung AC, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield GM, Janssen HL, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2016;43(2):283\u2013293. https:\/\/doi.org\/10.1111\/apt.13465","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"11088_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394\u2013419. https:\/\/doi.org\/10.1002\/hep.30145","journal-title":"Hepatology"},{"issue":"9","key":"11088_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa2306185","journal-title":"N Engl J Med"},{"issue":"9","key":"11088_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, et al. A phase 3 trial of Seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783\u2013794. https:\/\/doi.org\/10.1056\/NEJMoa2312100","journal-title":"N Engl J Med"},{"key":"11088_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/164_2019_241","volume":"256","author":"D Cabrera","year":"2019","unstructured":"Cabrera D, Arab JP, Arrese M. UDCA, NorUDCA, and TUDCA in liver diseases: a review of their mechanisms of action and clinical applications. Handb Exp Pharmacol. 2019;256:237\u2013264. https:\/\/doi.org\/10.1007\/164_2019_241","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"11088_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145\u2013172. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022","journal-title":"J Hepatol"},{"issue":"8","key":"11088_CR23","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/gutjnl-2019-319057","volume":"69","author":"MH Harms","year":"2020","unstructured":"Harms MH, de Veer RC, Lammers WJ, et al. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut. 2020;69(8):1502\u20131509. https:\/\/doi.org\/10.1136\/gutjnl-2019-319057","journal-title":"Gut"},{"issue":"4","key":"11088_CR24","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/hep.28712","volume":"64","author":"Y Xu","year":"2016","unstructured":"Xu Y, Li F, Zalzala M, et al. Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology. 2016;64(4):1072\u20131085. https:\/\/doi.org\/10.1002\/hep.28712","journal-title":"Hepatology"},{"issue":"2","key":"11088_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/8755122516687122","volume":"33","author":"SM Smith","year":"2017","unstructured":"Smith SM, Pegram AH. Obeticholic Acid: a Farnesoid X Receptor agonist for Primary Biliary Cholangitis. J Pharm Technol. 2017;33(2):66\u201371. https:\/\/doi.org\/10.1177\/8755122516687122","journal-title":"J Pharm Technol"},{"issue":"2","key":"11088_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","volume":"120","author":"KV Kowdley","year":"2025","unstructured":"Kowdley KV, Hirschfield GM, Coombs C, et al. COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls. Am J Gastroenterol. 2025;120(2):390\u2013400","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"11088_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s000110050622","volume":"49","author":"G Chinetti","year":"2000","unstructured":"Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49(10):497\u2013505. https:\/\/doi.org\/10.1007\/s000110050622","journal-title":"Inflamm Res"},{"issue":"3","key":"11088_CR28","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/hep.26894","volume":"59","author":"NS Ghonem","year":"2014","unstructured":"Ghonem NS, Ananthanarayanan M, Soroka CJ, Boyer JL. Peroxisome proliferator-activated receptor \u03b1 activates human multidrug resistance transporter 3\/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology. 2014;59(3):1030\u20131042. https:\/\/doi.org\/10.1002\/hep.26894","journal-title":"Hepatology"},{"issue":"1","key":"11088_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01070-3","volume":"7","author":"M Zhao","year":"2022","unstructured":"Zhao M, Wang L, Wang M, et al. Targeting fibrosis: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7(1): 206. https:\/\/doi.org\/10.1038\/s41392-022-01070-3","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"11088_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030913","volume":"19","author":"X Palomer","year":"2018","unstructured":"Palomer X, Barroso E, Pizarro-Delgado J, et al. PPAR\u03b2\/\u03b4: a key therapeutic target in metabolic disorders. Int J Mol Sci. 2018;19(3): 913. https:\/\/doi.org\/10.3390\/ijms19030913","journal-title":"Int J Mol Sci"},{"key":"11088_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100188","volume":"6","author":"F Colapietro","year":"2023","unstructured":"Colapietro F, Gershwin ME, Lleo A. PPAR agonists for the treatment of Primary Biliary Cholangitis: Old and new tales. J Transl Autoimmun. 2023;6: 100188. https:\/\/doi.org\/10.1016\/j.jtauto.2023.100188","journal-title":"J Transl Autoimmun"},{"issue":"23","key":"11088_CR32","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, et al. A placebo-controlled trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med. 2018;378(23):2171\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1714519","journal-title":"N Engl J Med"},{"key":"11088_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.948362","volume":"13","author":"X Guoyun","year":"2022","unstructured":"Guoyun X, Dawei D, Ning L, et al. Efficacy and safety of fenofibrate add-on therapy in patients with Primary Biliary Cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis. Front Pharmacol. 2022;13: 948362. https:\/\/doi.org\/10.3389\/fphar.2022.948362","journal-title":"Front Pharmacol"},{"issue":"3","key":"11088_CR34","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001.10.14309\/ajg.0000000000003029.PMID:39140490;PMCID:PMC11774195","volume":"160","author":"E de Vries","year":"2021","unstructured":"de Vries E, Bolier R, Goet J, et al. Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology. 2021;160(3):734-743.e6. https:\/\/doi.org\/10.1053\/j.gastro.2020.10.001.10.14309\/ajg.0000000000003029.PMID:39140490;PMCID:PMC11774195","journal-title":"Gastroenterology"},{"issue":"2","key":"11088_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/13543784.2020.1668375","volume":"29","author":"MJ Westerouen Van Meeteren","year":"2020","unstructured":"Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL. Elafibranor: A potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020;29(2):117\u2013123. https:\/\/doi.org\/10.1080\/13543784.2020.1668375. (PMID: 31523999)","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"11088_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102056","volume":"298","author":"T Kouno","year":"2022","unstructured":"Kouno T, Liu X, Zhao H, et al. Selective PPAR\u03b4 agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. J Biol Chem. 2022;298(7): 102056. https:\/\/doi.org\/10.1016\/j.jbc.2022.102056","journal-title":"J Biol Chem"},{"key":"11088_CR37","unstructured":"Vuppalanchi R, Caldwell SH, Pyrsopoulos N, et al. Results of a Phase 2, Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS). Gastroenterol Hepatol (N Y). 2021 Feb;17(2 Suppl 3):8. PMID: 34135713; PMCID: PMC8191832."},{"key":"11088_CR38","unstructured":"Zydus Therapeutics. Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III) [Internet]. 2025 [cited 2025 Aug 11]. Available from: ClinicalTrials.gov NCT05133336"},{"key":"11088_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13361","author":"S Joshita","year":"2019","unstructured":"Joshita S, Umemura T, Yamashita Y, et al. Biochemical and plasma lipid responses to Pemafibrate in patients with primary biliary cholangitis. Hepatol Res. 2019. https:\/\/doi.org\/10.1111\/hepr.13361. ([Epub ahead of print])","journal-title":"Hepatol Res"},{"issue":"1","key":"11088_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-020-0823-5","volume":"22","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020;22(1): 5. https:\/\/doi.org\/10.1007\/s11883-020-0823-5","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"11088_CR41","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/hepr.14172","volume":"55","author":"K Tsuji","year":"2025","unstructured":"Tsuji K, Tamaki N, Kurosaki M, et al. Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: nationwide, multicenter study by the Japanese Red Cross Liver Study Group. Hepatol Res. 2025;55(5):675\u2013684. https:\/\/doi.org\/10.1111\/hepr.14172","journal-title":"Hepatol Res"},{"issue":"4","key":"11088_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4166\/kjg.2021.092","volume":"78","author":"K Dohmen","year":"2021","unstructured":"Dohmen K, Onohara S, Harada S. Effects of switching from fenofibrate to pemafibrate for asymptomatic primary biliary cholangitis. Korean J Gastroenterol. 2021;78(4):227\u2013234. https:\/\/doi.org\/10.4166\/kjg.2021.092","journal-title":"Korean J Gastroenterol"},{"key":"11088_CR43","unstructured":"Kowa Research Institute, Inc. Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and\/or Obeticholic Acid (OCA) Treatment [Internet]. 2025 [cited 2025 Aug 11]. Available from: ClinicalTrials.gov NCT06247735"},{"issue":"10","key":"11088_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11102038","volume":"11","author":"D Matuz-Mares","year":"2022","unstructured":"Matuz-Mares D, V\u00e1zquez-Meza H, Vilchis-Landeros MM. NOX as a therapeutic target in liver disease. Antioxidants Basel. 2022;11(10): 2038. https:\/\/doi.org\/10.3390\/antiox11102038","journal-title":"Antioxidants Basel"},{"issue":"7","key":"11088_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129743","volume":"10","author":"T Lan","year":"2015","unstructured":"Lan T, Kisseleva T, Brenner DA. Deficiency of NOX1 or NOX4 prevents liver inflammation and fibrosis in mice through inhibition of hepatic stellate cell activation. PLoS ONE. 2015;10(7): e0129743. https:\/\/doi.org\/10.1371\/journal.pone.0129743","journal-title":"PLoS ONE"},{"key":"11088_CR46","unstructured":"Calliditas Therapeutics Suisse SA. A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM) [Internet]. 2025 [cited 2025 Aug 11]. Available from: ClinicalTrials.gov NCT05014672"},{"issue":"3","key":"11088_CR47","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","volume":"68","author":"MJ Mayo","year":"2023","unstructured":"Mayo MJ, Carey E, Smith HT, et al. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig Dis Sci. 2023;68(3):995\u20131005. https:\/\/doi.org\/10.1007\/s10620-022-07581-x","journal-title":"Dig Dis Sci"},{"issue":"1","key":"11088_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000216","volume":"23","author":"A Faisal","year":"2024","unstructured":"Faisal A. Understanding fatigue and pruritus in primary biliary cholangitis. Clin Liver Dis. 2024;23(1): e0216. https:\/\/doi.org\/10.1097\/CLD.0000000000000216","journal-title":"Clin Liver Dis"},{"issue":"1","key":"11088_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2023-001287","volume":"11","author":"U Gungabissoon","year":"2024","unstructured":"Gungabissoon U, Smith HT, von Maltzahn R, et al. Pruritus in primary biliary cholangitis is under-recorded in patient medical records. BMJ Open Gastroenterol. 2024;11(1): e001287. https:\/\/doi.org\/10.1136\/bmjgast-2023-001287","journal-title":"BMJ Open Gastroenterol"},{"issue":"16","key":"11088_CR50","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1080\/14656566.2022.2140040","volume":"23","author":"SM Bedoyan","year":"2022","unstructured":"Bedoyan SM, Lovell OT, Horslen SP, Squires JE. Odevixibat: a promising new treatment for progressive familial intrahepatic cholestasis. Expert Opin Pharmacother. 2022;23(16):1771\u20131779. https:\/\/doi.org\/10.1080\/14656566.2022.2140040","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"11088_CR51","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/psp4.13300","volume":"14","author":"F Carre\u00f1o","year":"2025","unstructured":"Carre\u00f1o F, Mehta R, de Souza AR, Collins J, Swift B. Analysis of C4 concentrations to predict impact of patient-reported diarrhea associated with the ileal bile acid transporter inhibitor linerixibat. CPT Pharmacomet Syst Pharmacol. 2025;14(3):596\u2013605. https:\/\/doi.org\/10.1002\/psp4.13300","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"11088_CR52","unstructured":"Mirum Pharmaceuticals, Inc. A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (VANTAGE) [Internet]. 2025 [cited 2025 Aug 11]. Available from: ClinicalTrials.gov NCT05050136"},{"issue":"7","key":"11088_CR53","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","volume":"21","author":"C Levy","year":"2023","unstructured":"Levy C, Kendrick S, Bowlus CL, Tanaka A, Jones D, Kremer AE, et al. GLIMMER: a randomized Phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus. Clin Gastroenterol Hepatol. 2023;21(7):1902-1912.e13. https:\/\/doi.org\/10.1016\/j.cgh.2022.10.032. (Study summary)","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"11088_CR54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","volume":"11","author":"GM Hirschfield","year":"2026","unstructured":"Hirschfield GM, Bowlus CL, Jones DEJ, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, Phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22\u201333. https:\/\/doi.org\/10.1016\/S2468-1253(25)00192-X","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"11088_CR55","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep4.1305","volume":"3","author":"MJ Mayo","year":"2019","unstructured":"Mayo MJ, Pockros PJ, Jones D, Bowlus CL, Levy C, Patanwala I, et al. A randomized, controlled, Phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3(3):365\u2013381. https:\/\/doi.org\/10.1002\/hep4.1305","journal-title":"Hepatol Commun"},{"key":"11088_CR56","unstructured":"Accessed from \u201cClinicalTrials.gov number, NCT05050136\u201d"},{"key":"11088_CR57","unstructured":"Accessed from \u201chttps:\/\/clinicaltrials.gov\/study\/NCT06016842\u201d"},{"key":"11088_CR58","unstructured":"Accessed from \u201chttps:\/\/clinicaltrials.gov\/study\/NCT06051617\u201d"},{"key":"11088_CR59","unstructured":"Created in BioRender. Sohal, A. (2026) https:\/\/BioRender.com\/ jixwv3v"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11088-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11088-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11088-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:57:58Z","timestamp":1783144678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11088-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["11088"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11088-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kris V. Kowdley\u00a0received grants from Akero, Boehringer Ingelheim, Boston Pharmaceuticals, Corcept, Gilead, GlaxoSmithKline, Ipsen, Madrigal, Mirum, Novo Nordisk, Zydus, and 89bio Inc.; received royalties or licenses from UpToDate; received consulting fees from: Boehringer Ingelheim, Gilead, GSK, Inipharm, Intercept, Ipsen, Madrigal, Mirum, Zydus, and 89bio Inc.; received honoraria for lecturing\/teaching from Madrigal, Gilead, Ipsen, Salix, and Novo Nordisk; has stock options in Inipharm.\u00a0Other authors do not have any disclosures to state.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The article does not contain any studies with human or animal subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving humans and\/or animal participants"}}]}}